The 19 analysts offering 12-month price forecasts for Biomarin Pharmaceutical Inc have a median target of 110.00, with a high estimate of 150.00 and a low estimate of 81.00. The median estimate represents a +42.05% increase from the last price of 77.44.
The current consensus among 19 polled investment analysts is to Buy stock in Biomarin Pharmaceutical Inc. This rating has held steady since February, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.10
Reporting Date TBD
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.